Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Wesolowski

Showing results (11-20 of 136) with videos related to

Pageof 14
Sort By:
Expert Review of Anticancer Therapy|April 7, 2022
Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer - a review of current evidence for and against the use of anti-HER2 treatment regimensKai Cc Johnson, Dionisia Quiroga, Preeti Sudheendra, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 14, 2018
Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitantEric Chau, Jordan Lundberg, Gary Phillips, et al.
Retinal Cases & Brief Reports|November 13, 2014
Hepatocellular carcinoma metastatic to uveaRobert Wesolowski, Jeffrey Yau-Huei Chung, Arun Singh, et al.
Cancer Treatment and Research Communications|July 13, 2019
Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinomaYoshihito David Saito, Zaibo Li, Maryam Lustberg, et al.
JAMA Network Open|August 24, 2023
Missing Components of Receptor Status Among Women With Invasive Breast CancerJulie A Stephens, James L Fisher, Robert Wesolowski, et al.
Investigational New Drugs|May 13, 2009
Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignanciesRobert Wesolowski, David Peereboom, Patricia Weiss, et al.
Breast Cancer Research and Treatment|July 6, 2013
Myeloid-derived suppressor cells in breast cancerJoseph Markowitz, Robert Wesolowski, Tracey Papenfuss, et al.
The Journal of Clinical and Aesthetic Dermatology|September 19, 2019
Spider Telangiectases and Palmar Erythema as Harbingers of Structural Liver Changes in Three Breast Cancer Patients on Ado-trastuzumab EmtansinePhilip Milam, Michael Berger, Bhuvaneswari Ramaswamy, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 10, 2014
Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitantJordan D Lundberg, Brooke Sorgen Crawford, Gary Phillips, et al.
The Annals of Pharmacotherapy|September 2, 2015
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast CancerNeha S Mangini, Robert Wesolowski, Bhuvaneswari Ramaswamy, et al.
Pageof 14

Showing results (11-20 of 136) with videos related to

Sort By:
Pageof 14
Expert Review of Anticancer Therapy|April 7, 2022
Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer - a review of current evidence for and against the use of anti-HER2 treatment regimensKai Cc Johnson, Dionisia Quiroga, Preeti Sudheendra, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 14, 2018
Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitantEric Chau, Jordan Lundberg, Gary Phillips, et al.
Retinal Cases & Brief Reports|November 13, 2014
Hepatocellular carcinoma metastatic to uveaRobert Wesolowski, Jeffrey Yau-Huei Chung, Arun Singh, et al.
Cancer Treatment and Research Communications|July 13, 2019
Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinomaYoshihito David Saito, Zaibo Li, Maryam Lustberg, et al.
JAMA Network Open|August 24, 2023
Missing Components of Receptor Status Among Women With Invasive Breast CancerJulie A Stephens, James L Fisher, Robert Wesolowski, et al.
Investigational New Drugs|May 13, 2009
Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignanciesRobert Wesolowski, David Peereboom, Patricia Weiss, et al.
Breast Cancer Research and Treatment|July 6, 2013
Myeloid-derived suppressor cells in breast cancerJoseph Markowitz, Robert Wesolowski, Tracey Papenfuss, et al.
The Journal of Clinical and Aesthetic Dermatology|September 19, 2019
Spider Telangiectases and Palmar Erythema as Harbingers of Structural Liver Changes in Three Breast Cancer Patients on Ado-trastuzumab EmtansinePhilip Milam, Michael Berger, Bhuvaneswari Ramaswamy, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 10, 2014
Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitantJordan D Lundberg, Brooke Sorgen Crawford, Gary Phillips, et al.
The Annals of Pharmacotherapy|September 2, 2015
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast CancerNeha S Mangini, Robert Wesolowski, Bhuvaneswari Ramaswamy, et al.
Pageof 14